<DOC>
	<DOCNO>NCT02627573</DOCNO>
	<brief_summary>Purpose There grow evidence high efficacy post-transplantation cyclophocphomide ( PTCy ) -based GVHD prophylaxis haploidentical match related unrelated bone marrow transplantation . There limitted , grow data safety efficacy prophylaxis unrelated peripheral blood stem cell transplantation . Use PTCy chronic myeloproliferative neoplasm myelodisplatic syndrome particular interest . On one hand , PTCy could reduce incidence chronic GVHD long-term bormidity . On hand , concern , PTCy increase incidence graft failure group patient . Currently publish data indicate low-dose Thymoglobulin-based prophylaxis promissing compatitor term acute chronic GVHD control . So rationale randomize Thymoglobulin PTCy GVHD prophilaxis . Pre-transplant assesment moratlity ( PAM ) -index use strata randomization , paramter take account important factor effect survival . The condition regimen two component GVHD prophylaxis ( mycophenolate mofetil tacrolimus ) identical two arm study .</brief_summary>
	<brief_title>Trial GVHD Prophylasxis With PTCy Thymoglobulin Unrelated SCT</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic , Atypical , BCR-ABL Negative</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Antineoplastic Agents , Alkylating</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients must indication allogeneic hematopoietic stem cell transplantation Diagnosis : Chronic myeloid leukemia Myelodysplastic Syndromes Myeloprolipherative neoplsm unclassified Atypical chronic myelogenous leukemia Signed informed consent Patients 10/10 HLAmatched unrelated donor available . The donor recipient must identical follow genetic locus : HLAA , HLAB , HLACw , HLADRB1 , HLADQB1 . Mismatches locus allow . Peripheral blood stem cell graft source No second tumor No prior history Thymoglobulin exposure history anaphylactic shock Thymoglobulin administration No severe concurrent illness Moderate severe cardiac dysfunction , leave ventricular ejection fraction &lt; 50 % Moderate severe decrease pulmonary function , FEV1 &lt; 70 % DLCO &lt; 70 % predict Respiratory distress &gt; grade I Severe organ dysfunction : AST ALT &gt; 5 upper normal limit , bilirubin &gt; 1.5 upper normal limit , creatinine &gt; 2 upper normal limit Creatinine clearance &lt; 60 mL/min Uncontrolled bacterial fungal infection time enrollment Requirement vasopressor support time enrollment Karnofsky index &lt; 30 % Pregnancy Somatic psychiatric disorder make patient unable sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Thymoglobulin</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Immunosuppressive Agents</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Mycophenolate mofetil</keyword>
	<keyword>Antineoplastic Agents , Alkylating</keyword>
	<keyword>Myeloablative Agonists</keyword>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>Allogeneic Transplantation</keyword>
	<keyword>Leukemia , Chronic Myeloid</keyword>
	<keyword>Leukemia , Myeloid , Chronic , Atypical , BCR-ABL Negative</keyword>
</DOC>